Meta-Analysis of Immunotherapy Trials for Advanced Cervical Cancer

1,491 patient records from 11 clinical trials evaluating immune checkpoint inhibitors combined with anti-angiogenic agents for advanced cervical cancer. The dataset, authored by Dezhi Zhang and last updated in May 2026, includes extracted outcome measures such as overall response rate, progression-free survival, and adverse events. It was compiled through a systematic review of databases including PubMed, Embase, and Cochrane Library.

Use Cases

• Calculate pooled efficacy metrics based on reported overall response rates and disease control rates.
• Assess treatment safety profiles based on reported adverse event rates and severity grades.
• Compare survival outcomes between combination therapy and control groups based on hazard ratios for overall and progression-free survival.
• Evaluate the robustness of meta-analysis findings based on sensitivity analyses and heterogeneity measures mentioned in the description.

Strengths

• Includes data from 11 trials (3 randomized controlled, 8 single-arm) with a total of 1,491 patients.
• Reports specific statistical outcomes, including hazard ratios with confidence intervals for survival endpoints.
• Systematic review methodology involved searching five major databases and is registered with PROSPERO.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 20.6 KB document, suggesting limited scope and likely containing summary results rather than raw patient-level data.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of published clinical trials.

Freshness

Last updated 2026-05-21 05:34:06